[Epidermal growth factor receptor in human breast cancer].
For the purpose of demonstrating the relationship between epidermal growth factor receptor (EGFR) content in the tumor and histopathologic characteristics, 45 women with breast cancer who underwent mastectomy were analyzed. EGFR content was measured by competitive binding assay using 125I, while EGFR was detected by immunocytochemical staining. Tumors with more than 1 fmol/mg protein EGFR were defined as positive, and a good correlation between competitive binding assay and staining was observed. Seventeen of them (37.8%) had EGFR-positive tumors. Eight of the 17 EGFR-positive tumors (47.1%) were positive for estrogen receptor (ER), whereas 24 of the 28 EGFR-negative tumors (85.7%) were ER-positive. This inverse relation was statistically significant (chi 2; p less than 0.05). Twelve of the 17 EGFR-positive cases (70.6%) had axillary node involvements, against 11 of the 28 (39.3%) in the EGFR-negative cases. There was no difference in the size of primary tumor between the two groups. These results suggested that EGFR-positive tumors have more malignant potency than EGFR-negative tumors. In 8 cases, EGFR content in metastatic axillary nodes was compared with that in primary tumors. More EGFR content indicated in metastatic axillary nodes than in primary tumors without significant difference.
Nakamura
T
T
Dept. of Surgery, Hiroshima University.
Hamada
Y
Y
Mukaida
H
H
Tanaka
T
T
Tanimoto
M
M
Niimoto
M
M
Hattori
T
T
D000911:Antibodies, Monoclonal; D001667:Binding, Competitive; D001943:Breast Neoplasms / Q000032:analysis* / Q000473:pathology; D066246:ErbB Receptors / Q000032:analysis*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D011960:Receptors, Estrogen / Q000032:analysis; D013194:Staining and Labeling
D000911:Antibodies, Monoclonal; D011960:Receptors, Estrogen; D066246:ErbB Receptors